Tissue repairFDA Approved (Compounding)

Glutathione

A tripeptide antioxidant composed of glutamate, cysteine, and glycine, central to cellular detoxification, immune function, and oxidative stress defense.

AntioxidantDetoxImmuneSkin

Also referenced as: GSH, L-Glutathione, Reduced Glutathione

Also appears in: Longevity

Price compare
120 tracked offers across 120 vendors · 18 dosages
Best trust-adjusted value: IDUN Peptides · Strong trust · $0.02/mg
From
$0.02/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

-1.1%vs. Aug 10
Current low$0.03/mg
Market median$0.06/mg
Current coverage54 vendors
Observed window90 daily points
Lowest effective priceMarket median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Glutathione crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence137 certificate records mentioning this compound or product name88 provider-linked · 118 exact product matches
Status
FDA Approved (Compounding)

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Tissue-repair research

Primary research area: Tissue repair. Also surfaces under Longevity for browsing and discovery.

Aliases
3

GSH, L-Glutathione, Reduced Glutathione

Signal depth
Medium

FDA label signal · 1541 trials · 197433 PubMed results

Early
Research evidence

Glutathione has human trials registered, but none have reported controlled results yet. Most current claims about what it does in people rest on preclinical (lab or animal) work, not published human data.

Glutathione has 4 name-matched clinical trials (1 international) (highest phase: no phased trial) and 197525 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.

🌍 1 international trial
Human data
Human (non-phased)
Trial quality
Randomized
Outcomes
Surrogate / early
Replication
Meta-analysis
Literature
Top-tier journals
NA · RandomizedThe Impact of Oral Glutathione on Oxidative Damage and Glycated Hemoglobin (HbA1c) Levels in Type 2 Diabetes PatientsNA · RandomizedEffect of Glutathione vs KI in Reducing SDF Staining When Used in Treatment of Primary Carious TeethNA · RandomizedGlutathione Metabolism in Adolescents With Type 1 Diabetes - Study AISRCTNA study on whether a natural sulforaphane supplement can boost glutathione levelsCellular Physiology and Biochemistry · 47,289 citationsShort-Term Effects of Nose-Only Cigarette Smoke Exposure on Glutathione Redox Homeostasis, Cytochrome P450 1A1/2 and Respiratory Enzyme Activities in Mice TissuesJournal of Biological Chemistry · 18,198 citationsGlutathione S-Transferases
Evidence history
  1. 2026-09-05Promising→EarlyBand Promising → Early; -77 trials; +36 PubMed
  2. 2026-09-04Early→PromisingBand Early → Promising; +15 trials; +44 PubMed
  3. 2026-09-03Promising→EarlyBand Promising → Early; +65 PubMed
  4. 2026-08-28Early→PromisingBand Early → Promising; -46 trials; +35 PubMed
  5. 2026-08-27Promising→EarlyBand Promising → Early; +31 trials; +137 PubMed
  6. 2026-08-25Early→PromisingBand Early → Promising; +46 trials; +32 PubMed
  7. 2026-08-20Promising→EarlyBand Promising → Early; -46 trials; +37 PubMed
  8. 2026-08-15Early→PromisingBand Early → Promising; +30 trials; +27 PubMed
  9. 2026-08-14Promising→EarlyBand Promising → Early; +86 PubMed
  10. 2026-08-12Early→PromisingBand Early → Promising; +30 trials; +28 PubMed
  11. 2026-08-09Promising→EarlyBand Promising → Early; -15 trials; +96 PubMed
  12. 2026-07-29Early→PromisingBand Early → Promising; +60 trials; +151 PubMed
  13. 2026-07-28Promising→EarlyBand Promising → Early; -30 trials; +46 PubMed
  14. 2026-07-23Early→PromisingBand Early → Promising; +60 trials; +39 PubMed
  15. 2026-07-21Promising→EarlyBand Promising → Early; -45 trials; +26 PubMed
  16. 2026-07-17Early→PromisingBand Early → Promising; -15 trials; +38 PubMed

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What is glutathione?

Glutathione (GSH) is a tripeptide — gamma-glutamylcysteinylglycine — produced endogenously in every human cell. It is the body’s most abundant intracellular antioxidant and plays critical roles in Phase II detoxification, immune cell function, and redox signaling.

How it works

  • Direct antioxidant — GSH neutralizes reactive oxygen species (ROS) and reactive nitrogen species by donating electrons, becoming oxidized glutathione (GSSG) in the process (Forman et al., Archives of Biochemistry and Biophysics, 2009)
  • Conjugation reactions — glutathione S-transferases (GSTs) conjugate GSH to xenobiotics and endogenous toxins, facilitating their excretion (Hayes et al., Annual Review of Pharmacology and Toxicology, 2005)
  • Immune modulation — T-lymphocyte proliferation and natural killer cell activity depend on intracellular GSH levels (Dröge & Breitkreutz, Proceedings of the Nutrition Society, 2000)

Clinical use

Unlike most research peptides, glutathione has established medical applications:

  • Acetaminophen toxicity — IV N-acetylcysteine (a GSH precursor) is standard of care
  • Compounding pharmacies — injectable glutathione is available via prescription for off-label uses
  • Parkinson’s disease — IV glutathione has been studied as adjunctive therapy, though results are mixed (Mischley et al., Movement Disorders, 2017)
  • Skin lightening — widely used in aesthetic medicine; a systematic review found limited but suggestive evidence for melanin reduction (Weschawalit et al., Journal of Clinical and Aesthetic Dermatology, 2017)

Research status

Glutathione has extensive published literature (>170,000 PubMed entries). Key clinical references:

  • Richie et al. (2015) showed oral GSH supplementation increased body stores of glutathione in a randomized trial (European Journal of Nutrition, 54(2):251–263)
  • Allen & Bradley (2011) reviewed glutathione’s role in oxidative stress and aging (Age, 33(2):199–212)
  • Weschawalit et al. (2017) demonstrated skin-lightening effects of oral glutathione in a randomized, double-blind trial (Journal of Clinical and Aesthetic Dermatology, 10(10):14–17)

Key considerations

  • Available as IV, subcutaneous, oral, and sublingual formulations
  • Oral bioavailability is debated — liposomal and sublingual forms may improve absorption
  • Research vendor injectable formulations differ from pharmacy-compounded versions in quality oversight